Last reviewed · How we verify
Placebo cagrilintide
Placebo cagrilintide is a Amylin receptor agonist Small molecule drug developed by Novo Nordisk A/S. It is currently in Phase 3 development for Chronic weight management in adults with obesity or overweight with weight-related comorbidities (Phase 3). Also known as: Cagrilintide A, NNC0174-0833 A.
Cagrilintide is an amylin receptor agonist that slows gastric emptying and promotes satiety to reduce appetite and food intake.
Cagrilintide is a protein-based medication being studied for its potential effects on conditions such as type 2 diabetes, diabetic peripheral neuropathy, obesity, and overweight. It is being investigated in combination with semaglutide, and its exact mechanism of action is not specified in the available information.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Novo Nordisk A/S is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo cagrilintide |
|---|---|
| Also known as | Cagrilintide A, NNC0174-0833 A |
| Sponsor | Novo Nordisk A/S |
| Drug class | Amylin receptor agonist |
| Target | Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 1) |
| Modality | Small molecule |
| Therapeutic area | Obesity / Metabolic disease |
| Phase | Phase 3 |
Mechanism of action
Cagrilintide mimics amylin, a hormone co-secreted with insulin that regulates postprandial glucose levels and promotes feelings of fullness. By activating amylin receptors in the brain and gastrointestinal tract, it delays stomach emptying and enhances satiety signaling, leading to reduced caloric intake and weight loss. It is being developed as a combination therapy with GLP-1 receptor agonists for enhanced weight management efficacy.
Approved indications
- Chronic weight management in adults with obesity or overweight with weight-related comorbidities (Phase 3)
Common side effects
- Nausea
- Vomiting
- Gastrointestinal disturbances
- Injection site reactions
Key clinical trials
- Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease (PHASE2)
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels (PHASE3)
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (PHASE3)
- Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes (PHASE1)
- A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight (PHASE3)
- Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide (PHASE3)
- A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes (PHASE2)
- A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo cagrilintide CI brief — competitive landscape report
- Placebo cagrilintide updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about Placebo cagrilintide
What is Placebo cagrilintide?
How does Placebo cagrilintide work?
What is Placebo cagrilintide used for?
Who makes Placebo cagrilintide?
Is Placebo cagrilintide also known as anything else?
What drug class is Placebo cagrilintide in?
What development phase is Placebo cagrilintide in?
What are the side effects of Placebo cagrilintide?
What does Placebo cagrilintide target?
Related
- Drug class: All Amylin receptor agonist drugs
- Target: All drugs targeting Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 1)
- Manufacturer: Novo Nordisk A/S — full pipeline
- Therapeutic area: All drugs in Obesity / Metabolic disease
- Indication: Drugs for Chronic weight management in adults with obesity or overweight with weight-related comorbidities (Phase 3)
- Also known as: Cagrilintide A, NNC0174-0833 A
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing